202 related articles for article (PubMed ID: 27666539)
1. Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.
Procházka V; Papajík T; Janíková A; Belada D; Kozák T; Šálek D; Sýkorová A; Móciková H; Campr V; Dlouhá J; Langová K; Fürst T; Trněný M
Leuk Lymphoma; 2017 Mar; 58(3):601-613. PubMed ID: 27666539
[TBL] [Abstract][Full Text] [Related]
2. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
[TBL] [Abstract][Full Text] [Related]
5. [Follicular lymphoma. High-dose immunochemotherapy with autologous blood stem cell transplantation: Results of the first prospective study in Russia].
Nesterova ES; Kravchenko SK; Mangasarova YK; Baryakh EA; Misyurina AE; Vorobyev VI; Plastinina LV; Chernova NG; Kovrigina AM; Obukhova TN; Klyasova GA; Shevelev AA; Kostina IE; Gemdzhian EG; Gaponova TV; Vorobyev AI
Ter Arkh; 2016; 88(7):62-71. PubMed ID: 27459617
[TBL] [Abstract][Full Text] [Related]
6. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.
Bruna R; Benedetti F; Boccomini C; Patti C; Barbui AM; Pulsoni A; Musso M; Liberati AM; Gini G; Castellino C; Rossini F; Ciceri F; Rota-Scalabrini D; Stelitano C; Di Raimondo F; Tucci A; Devizzi L; Zoli V; Zallio F; Narni F; Dondi A; Parvis G; Semenzato G; Lanza F; Perrone T; Angrilli F; Billio A; Gueli A; Mantoan B; Rambaldi A; Gianni AM; Corradini P; Passera R; Ladetto M; Tarella C
Haematologica; 2019 Nov; 104(11):2241-2248. PubMed ID: 31666344
[TBL] [Abstract][Full Text] [Related]
7. The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group.
Belada D; Prochazka V; Janikova A; Campr V; Blahovcova P; Pytlik R; Sykorova A; Klener P; Benesova K; Pirnos J; Duras J; Mocikova H; Trneny M
Leuk Res; 2018 Oct; 73():29-38. PubMed ID: 30195062
[TBL] [Abstract][Full Text] [Related]
8. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
9. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
Provencio M; Cruz Mora MÁ; Gómez-Codina J; Quero Blanco C; Llanos M; García-Arroyo FR; de la Cruz L; Gumá Padró J; Delgado Pérez JR; Sánchez A; Alvarez Cabellos R; Rueda A;
Leuk Lymphoma; 2014 Jan; 55(1):51-5. PubMed ID: 23573825
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States.
Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Taylor M; Friedberg JW; Koff JL; Link BK; Cerhan JR; Dawson KL; Flowers CR
Leuk Lymphoma; 2015 May; 56(5):1295-302. PubMed ID: 25263322
[TBL] [Abstract][Full Text] [Related]
11. FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy.
Prochazka V; Papajik T; Gazdova J; Divoka M; Rozmanova S; Faber E; Raida L; Kucerova L; Langova K; Jarosova M; Indrak K
Neoplasma; 2011; 58(3):263-70. PubMed ID: 21395368
[TBL] [Abstract][Full Text] [Related]
12. Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource.
Wudhikarn K; Smith BJ; Button AM; Habermann TM; Thompson CA; Rosenstein LJ; Syrbu SI; Weiner GJ; Cerhan JR; Link BK
Leuk Lymphoma; 2015; 56(8):2365-72. PubMed ID: 25530345
[TBL] [Abstract][Full Text] [Related]
13. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova J; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Leuk Lymphoma; 2016 May; 57(5):1094-103. PubMed ID: 26293000
[TBL] [Abstract][Full Text] [Related]
14. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M
J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
16. Impact of age on clinical risk scores in follicular lymphoma.
Alig S; Jurinovic V; Pastore A; Haebe S; Schmidt C; Zoellner AK; Dreyling M; Unterhalt M; Hoster E; Hiddemann W; Weigert O
Blood Adv; 2019 Apr; 3(7):1033-1038. PubMed ID: 30940638
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
Gyan E; Sonet A; Brice P; Anglaret B; Laribi K; Fruchart C; Tilly H; Araujo C; Soubeyran P; Gonzalez H; Morineau N; Nicolas-Virelizier E; Ghesquières H; Salles B; Bouabdallah R; Orfeuvre H; Fahri J; Couturier O; Xerri L; Feugier P;
Br J Haematol; 2018 Oct; 183(1):76-86. PubMed ID: 30117149
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
[TBL] [Abstract][Full Text] [Related]
20. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D
Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
